Patents Assigned to Cephalon, Inc.
  • Patent number: 10906973
    Abstract: The present invention relates, in general, to polypeptides capable of transmigrating the blood-brain barrier, and uses thereof. More specifically, the present invention relates to polypeptides derived by site-directed mutagenesis of an existing antibody fragment and uses thereof, and methods of making such molecules. The polypeptides of the present invention show enhanced blood-brain barrier crossing and brain exposure levels in vitro and in vivo.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: February 2, 2021
    Assignees: National Research Council of Canada, Cephalon, Inc.
    Inventors: Danica Stanimirovic, Traian Sulea, Kristin Kemmerich, David Wilson, Jennifer Stratton, Matthew Pollard, Adam Clarke
  • Patent number: 10632119
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 28, 2020
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Publication number: 20200095316
    Abstract: The present invention relates, in general, to polypeptides capable of transmigrating the blood-brain barrier, and uses thereof. More specifically, the present invention relates to polypeptides derived by site-directed mutagenesis of an existing antibody fragment and uses thereof, and methods of making such molecules. The polypeptides of the present invention show enhanced blood-brain barrier crossing and brain exposure levels in vitro and in vivo.
    Type: Application
    Filed: December 12, 2017
    Publication date: March 26, 2020
    Applicants: National Research Council of Canada, Cephalon, Inc.
    Inventors: Danica Stanimirovic, Traian Sulea, Kristin Kemmerich, David Wilson, Jennifer Stratton, Matthew Pollard, Adam Clarke
  • Patent number: 10577414
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to the patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 3, 2020
    Assignee: Cephalon, Inc.
    Inventors: Christopher O'Brien, James Zangrilli, Tushar Shah, Guy Brusselle
  • Patent number: 10517852
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: December 31, 2019
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Publication number: 20190240348
    Abstract: The disclosure provides compounds of Formula (I), wherein X, Y, and Z are defined herein. The disclosure also provides particles comprising one or more compounds described herein, compositions comprising one or more compounds or particles described herein and a pharmaceutically acceptable carrier, and methods of treating a subject in need thereof comprising administering one or more compounds, particles, or compositions described herein to the subject. X—Y—Z??(I).
    Type: Application
    Filed: July 13, 2017
    Publication date: August 8, 2019
    Applicant: Cephalon, Inc.
    Inventors: Anthony S. DRAGER, Paritosh WATTAMWAR
  • Patent number: 10259794
    Abstract: The present disclosure is directed to improved methods useful for the preparation of, for example, 2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5Hbenzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methyl-benzamide (CEP-37440).
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 16, 2019
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Roger P. Bakale, Dale R. Mowrey, Daniel E. Petrillo, Sander Kluwer
  • Patent number: 10201506
    Abstract: The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: February 12, 2019
    Assignee: CEPHALON, INC.
    Inventors: Peter D. Brown, Anthony S. Drager
  • Patent number: 10150772
    Abstract: The present disclosure relates to crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, including salts forms and free base forms.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: December 11, 2018
    Assignee: CEPHALON, INC.
    Inventors: Stephen J. Bierlmaier, Ralph C. Haltiwanger, Martin J. Jacobs
  • Patent number: 10138296
    Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: November 27, 2018
    Assignee: Cephalon, Inc.
    Inventors: Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget Ann Cooksey, Vanya Pande, Adam William Clarke
  • Patent number: 10111872
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: October 30, 2018
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Patent number: 10039750
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: August 7, 2018
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Patent number: 9902696
    Abstract: Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: February 27, 2018
    Assignee: Cephalon, Inc.
    Inventors: Nadine C. Becknell, Reddeppa Reddy Dandu, Bruce D. Dorsey, Dimitar B. Gotchev, Robert L. Hudkins, Linda Weinberg, Craig A. Zificsak, Allison L. Zulli
  • Patent number: 9815894
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to a patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: November 14, 2017
    Assignee: Cephalon, Inc.
    Inventors: Christopher O'Brien, James Zangrilli, Tushar Shah
  • Publication number: 20170267683
    Abstract: The present disclosure relates to crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, including salts forms and free base forms.
    Type: Application
    Filed: November 25, 2015
    Publication date: September 21, 2017
    Applicant: CEPHALON, INC.
    Inventors: Stephen J. BIERLMAIER, Ralph C. HALTIWANGER, Martin J. JACOBS
  • Patent number: 9623026
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 18, 2017
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Patent number: 9598377
    Abstract: The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 21, 2017
    Assignee: Cephalon, Inc.
    Inventors: Peter D. Brown, Anthony S. Drager
  • Patent number: 9533955
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: January 3, 2017
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Patent number: 9487529
    Abstract: The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: November 8, 2016
    Assignee: Cephalon, Inc.
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Gregory R. Ott
  • Patent number: 9475766
    Abstract: Compounds of formula II are described: wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: October 25, 2016
    Assignees: Cephalon, Inc., University of Utah Research Foundation, University of Hawaii
    Inventors: Bruce D. Dorsey, Scott K. Kuwada, Jay P. Theroff, Craig A. Zificsak